Shehnaaz Suliman Sells 2,207 Shares of 10x Genomics (NASDAQ:TXG) Stock

10x Genomics (NASDAQ:TXG) Director Shehnaaz Suliman sold 2,207 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $63.65, for a total value of $140,475.55. Following the completion of the sale, the director directly owned 29,515 shares of the company’s stock, valued at approximately $1,878,629.75. The trade was a 6.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shehnaaz Suliman also recently made the following trade(s):

• On Tuesday, June 16th, Shehnaaz Suliman sold 5,723 shares of 10x Genomics stock. The stock was sold at an average price of $32.63, for a total value of $186,741.49.

10x Genomics Price Performance

Shares of TXG stock opened at $64.85 on Friday. The business’s 50 day simple moving average is $47.62 and its 200 day simple moving average is $31.62. 10x Genomics has a one year low of $11.16 and a one year high of $66.94. The stock has a market capitalization of $8.45 billion, a PE ratio of -109.91 and a beta of 2.03.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.10. The firm had revenue of $151.04 million during the quarter, compared to analyst estimates of $146.67 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The company’s revenue was down 12.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.28 EPS. As a group, research analysts expect that 10x Genomics will post -0.75 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on TXG. Stifel Nicolaus set a $50.00 target price on shares of 10x Genomics in a report on Friday, August 7th. TD Cowen reaffirmed a “hold” rating on shares of 10x Genomics in a research report on Wednesday, July 15th. Citigroup increased their price target on 10x Genomics from $45.00 to $50.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Canaccord Genuity Group lifted their price objective on 10x Genomics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Morgan Stanley boosted their price objective on 10x Genomics from $37.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and a consensus target price of $38.31.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Recent quarterly results offered some fundamental support: 10x Genomics reported an adjusted loss of $0.14 per share, better than the expected $0.24 loss, while revenue of $151.0 million exceeded estimates of $146.7 million. Several analysts subsequently raised their price targets, including Stephens to $65 and Canaccord Genuity to $60.
• Neutral Sentiment: CEO Serge Saxonov, CFO Adam Taich and insider Benjamin Hindson sold a combined approximately $3.12 million of shares. The transactions reduced their holdings by 1.68% to 4.52% and were reported as sales to cover tax obligations from vested equity awards, making them a less negative signal than discretionary insider selling. Each continues to hold a substantial position. Insider sales report CEO sale report
• Negative Sentiment: Director Shehnaaz Suliman sold 2,207 shares for approximately $140,476, reducing her direct ownership by 6.96%. The filing did not identify tax withholding as the reason, creating a modestly cautious insider signal. Director sale report
• Negative Sentiment: 10x Genomics remains unprofitable, with analysts expecting a full-year loss of approximately $0.75 per share. Revenue also declined 12.7% year over year in the latest quarter, while the consensus price target of $38.31 is substantially below the stock’s recent level, highlighting valuation and execution risk after its sharp rally.

Institutional Trading of 10x Genomics

Several hedge funds have recently modified their holdings of TXG. Sei Investments Co. boosted its position in shares of 10x Genomics by 113.5% during the 1st quarter. Sei Investments Co. now owns 44,679 shares of the company’s stock worth $949,000 after purchasing an additional 23,748 shares in the last quarter. Hsbc Holdings PLC bought a new stake in 10x Genomics in the 1st quarter valued at about $5,945,000. Simplify Asset Management Inc. bought a new stake in 10x Genomics in the 4th quarter valued at about $7,926,000. Clough Capital Partners L P acquired a new position in 10x Genomics during the 4th quarter worth approximately $9,955,000. Finally, Cookson Peirce & Co. Inc. acquired a new position in 10x Genomics during the 4th quarter worth approximately $571,000. Institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.